In primary care practice, we do not see GLP-1 agonists being commonly used for diabetes control for several reasons including cost and because it is administered by injection. Was adherence to liraglutide measured in some way during the trial? If so, how was it assessed? This would be interesting to know since if GLP-1 agonists are recommended for weight loss therapy in the future, patient adherence will be a big issue.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.